7Baggers

Gossamer Bio, Inc
(NASDAQ:GOSS) 

GOSS stock logo

Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology in the United States. It is developing GB001, an oral antagonist of prostaglandin D2 receptor...

Founded: 2015
Full Time Employees: 171
Sector: Healthcare
Industry: Biotechnology
Pharmaceuticals
Share this website to your friends
• Market Cap:
• Exchange:
• Shs Outstanding:
• Employees:
• Beta:
• Return on Equity (ROE) ttm:
• Return on Assets (ROA) ttm:
• EPS ttm:
• Book value per Share:
• Cash per Share:
• Current ast per Share:
• P/E ttm:
• P/E forward:
• P/E ttm high:
• P/E ttm low:
• P/S ttm:
• P/B ttm:
• P/FCF ttm:
• PEG ratio:
• Cash Ratio ttm:
• Quick Ratio ttm:
• Current Ratio ttm:
• Gross Mgn ttm:
• EBITDA Mgn ttm:
• Operating Mgn ttm:
• Net Income Mgn ttm:
• Trailing Div yield:
• Forward Div yield:
• Payout Ratio ttm:
• Ex-Dividend date:
• Target Price High:
• Target Price Low:
• Target Price Mean:
• Number of Analysts:
• Debt Ratio ttm:
• Debt to Equity ttm:
• Total Net Debt:
At a glance:
Bull Thesis:
Bear Thesis:
Main Competitors:
Moat:
Income Statements:
Quarterly
Annual
    Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 
                                  
      revenue:
    		                              
      revenue from contracts with collaborators
    		16,955,000 13,799,000 13,294,000 11,489,000 9,889,000 7,448,000 9,480,000 7,091,000                       
      total revenue
    		16,955,000 13,799,000 13,294,000 11,489,000 9,889,000 9,379,000 9,480,000 95,842,000                       
      yoy
    		71.45% 47.13% 40.23% -88.01%                           
      qoq
    		22.87% 3.80% 15.71% 16.18% 5.44% -1.07% -90.11%                        
      operating expenses:
    		                              
      research and development
    		43,075,000 48,935,000 45,542,000 41,575,000 38,041,000 36,112,000 34,897,000 35,086,000 32,392,000 29,970,000 31,200,000 36,309,000 37,795,000 41,508,000 44,509,000 42,580,000 42,322,000 40,932,000 43,190,000 44,318,000 41,827,000 38,910,000 41,846,000 38,684,000 41,414,000 42,596,000 40,148,000 35,676,000 24,983,000  
      general and administrative
    		18,746,000 10,904,000 9,390,000 8,679,000 8,658,000 9,395,000 8,502,000 8,669,000 9,567,000 9,057,000 9,290,000 9,976,000 10,132,000 12,834,000 11,497,000 11,277,000 12,001,000 10,714,000 12,459,000 11,263,000 11,346,000 15,877,000 11,448,000 11,655,000 10,748,000 11,592,000 9,838,000 9,673,000 8,034,000  
      total operating expenses
    		61,821,000 59,838,000 62,408,000 50,254,000 46,699,000 45,507,000 43,399,000 43,755,000 41,959,000 49,027,000 40,490,000 46,300,000 47,942,000 54,357,000 56,021,000 53,872,000 54,343,000 51,661,000 55,664,000 55,596,000 53,203,000 60,087,000 53,569,000 65,339,000 54,967,000 55,788,000 49,986,000 46,349,000 34,017,000  
      income from operations
    		-44,866,000 -46,039,000 -49,114,000 -38,765,000 -36,810,000 -36,128,000 -33,919,000 52,087,000 -41,959,000 -49,027,000 -40,490,000 -46,300,000 -47,942,000 -54,357,000 -56,021,000 -53,872,000 -54,343,000 -51,661,000 -55,664,000 -55,596,000 -53,203,000 -60,087,000 -53,569,000 -65,339,000 -54,967,000 -55,788,000 -49,986,000 -46,349,000 -34,017,000  
      yoy
    		21.89% 27.43% 44.80% -174.42% -12.27% -26.31% -16.23% -212.50% -12.48% -9.81% -27.72% -14.06% -11.78% 5.22% 0.64% -3.10% 2.14% -14.02% 3.91% -14.91% -3.21% 7.71% 7.17% 40.97% 61.59%      
      qoq
    		-2.55% -6.26% 26.70% 5.31% 1.89% 6.51% -165.12% -224.14% -14.42% 21.08% -12.55% -3.42% -11.80% -2.97% 3.99% -0.87% 5.19% -7.19% 0.12% 4.50% -11.46% 12.17% -18.01% 18.87% -1.47% 11.61% 7.85% 36.25%   
      operating margin %
    		-264.62% -333.64% -369.44% -337.41% -372.23% -385.20% -357.80% 54.35% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity%  
      other income
    		603,000 1,017,000 2,954,000 2,694,000 2,624,000 4,171,000 4,288,000 2,747,000 2,816,000 3,808,000 3,420,000 6,538,000 1,690,000 1,456,000 -332,000 587,000 -199,000 78,000 115,000 457,000 149,000 4,707,000 -4,243,000 -1,531,000 893,000 1,090,000 1,486,000 1,851,000 376,000  
      interest income
    		354,000 447,000 687,000 542,000 294,000 -744,000 430,000 1,749,000 344,000 310,000 405,000 695,000 587,000 594,000 465,000 300,000 224,000 236,000 191,000 141,000 193,000        1,049,000  
      interest expense
    		-2,755,000 -2,751,000 -2,748,000 -2,744,000 -2,746,000 -2,738,000 -2,734,000 -2,916,000 -3,129,000 -3,239,000 -3,343,000 -3,429,000 -3,500,000 -3,457,000 -3,475,000 -3,481,000 -3,467,000 -4,937,000 -4,889,000 -4,834,000 -4,780,000        -19,000  
      total other income
    		-1,798,000 -1,287,000 893,000 492,000 172,000 689,000 1,984,000 1,580,000 31,000 879,000 482,000 3,804,000     -3,442,000    -4,438,000        1,406,000  
      net income
    		-46,664,000 -47,238,000 -48,221,000 -38,273,000 -36,638,000 -33,029,000 -30,803,000 49,232,000 -41,928,000 -48,148,000 -40,008,000 -42,496,000 -49,165,000 -55,764,000 -59,363,000 -56,466,000 -57,785,000 -56,284,000 -60,247,000 -59,832,000 -57,641,000 -64,604,000 -57,812,000 -66,870,000 -54,074,000 -54,698,000 -48,500,000 -44,498,000 -32,611,000  
      yoy
    		27.37% 43.02% 56.55% -177.74% -12.62% -31.40% -23.01% -215.85% -14.72% -13.66% -32.60% -24.74% -14.92% -0.92% -1.47% -5.63% 0.25% -12.88% 4.21% -10.52% 6.60% 18.11% 19.20% 50.28% 65.82%      
      qoq
    		-1.22% -2.04% 25.99% 4.46% 10.93% 7.23% -162.57% -217.42% -12.92% 20.35% -5.85% -13.56% -11.83% -6.06% 5.13% -2.28% 2.67% -6.58% 0.69% 3.80% -10.78% 11.75% -13.55% 23.66% -1.14% 12.78% 8.99% 36.45%   
      net income margin %
    		-275.22% -342.33% -362.73% -333.13% -370.49% -352.16% -324.93% 51.37% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity% -Infinity%  
      other comprehensive income:
    		                              
      foreign currency translation
    		1,192,000 -20,000 -130,000 -4,195,000 -1,903,000 3,694,000 -2,260,000 135,000 -119,000 179,000 -170,000 1,000 23,000 -225,000 -173,000 -138,000               
      unrealized loss on marketable securities
    		-67,000   -69,000 -110,000           -36,000               
      other comprehensive income
    		1,125,000   -4,264,000    110,000 -278,000   -45,000 138,000 11,000 -71,000 -174,000  -92,000 -137,000 116,000  257,000 -225,000 1,072,000 -763,000 -70,000 -168,000 417,000   
      comprehensive loss
    		-45,539,000 -47,280,000 -48,240,000  -38,651,000 -29,609,000 -32,516,000  -42,206,000 -47,880,000 -40,145,000 -42,541,000 -49,027,000 -55,753,000 -59,434,000 -56,640,000 -58,170,000 -56,376,000 -60,384,000 -59,716,000 -58,082,000 -64,347,000 -58,037,000 -65,798,000 -54,837,000 -54,768,000 -48,668,000 -44,081,000 -32,471,000  
      net income per share
    		-0.2 -0.21 -0.21 -0.17 -0.16 -0.15 -0.14 0.22 -0.19 -0.15 -0.21 -0.45 -0.52 -0.57 -0.65 -0.74 -0.76 -0.75 -0.8 -0.8 -0.78 -0.88 -0.8 -1 -0.87 -0.9 -0.8 -0.74 -0.9  
      weighted-average common shares outstanding, basic and diluted
    		234,137,364 228,519,130 227,981,475  226,818,051 226,228,016 226,346,058  225,735,236 152,621,669 192,883,209 95,446,929 94,870,293 84,574,869 91,181,427 76,668,162 75,894,692 74,843,482 75,001,510 74,672,882 74,093,526 68,510,260 72,245,897 66,599,915 61,890,323 54,740,170 60,755,872 60,265,046 36,317,230  
      revenue from sale of licenses
    		     1,931,000  88,751,000                       
      in process research and development
    		 -1,000 7,476,000         15,000 15,000 15,000 15,000 15,000 20,000 15,000 15,000 15,000 30,000 5,300,000 275,000 15,000,000 2,805,000 1,600,000  1,000,000 1,000,000  
      income before provision for income taxes
    		 -47,326,000 -48,221,000 -38,273,000  -35,439,000 -31,935,000 53,667,000                       
      provision for income taxes
    		     -2,410,000 -1,132,000 4,435,000                       
      unrealized gain on marketable securities
    		 -17,000 111,000   90,750 547,000 -25,000 -159,000 25,500 33,000 -46,000 115,000 -77,750 102,000                
      other comprehensive loss
    		 -1,574,000 -19,000  -2,013,000 -470,250 -1,713,000   -11,000 -137,000      -385,000    -441,000        140,000  
      comprehensive income
    		   -42,537,000    49,342,000                       
      weighted-average common shares outstanding, basic
    		   227,275,466    226,221,202                       
      weighted-average common shares outstanding, diluted
    		   227,275,466    238,543,102                       
      other comprehensive loss:
    		                              
      other expense
    		                              
      total other expense
    		            -1,223,000 -1,407,000 -3,342,000 -2,594,000  -3,314,250 -4,583,000 -4,236,000           
      foreign currency translation, net of tax
    		                -8,000 -55,000 -64,000 162,000 -372,000 382,000 68,000 78,000 -87,000      
      unrealized loss on marketable securities, net of tax
    		                -377,000    -69,000          
      unrealized gain on marketable securities, net of tax
    		                 -37,000 -73,000 -46,000  -125,000 -293,000 994,000 -676,000 -58,000 -168,000 417,000 140,000  
    Balance Sheets:
    Quarterly
    Annual
      Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 2018-12-31 
                                    
        assets
      		                              
        current assets
      		                              
        cash and cash equivalents
      		41,028,000 37,732,000 8,933,000 26,309,000 29,021,000 46,074,000 28,464,000 86,877,000 38,863,000 32,109,000 82,609,000 37,004,000 65,242,000 111,973,000 153,477,000 94,316,000 138,907,000 183,403,000 213,474,000 342,453,000 439,659,000 486,055,000 461,956,000 486,062,000 111,353,000 135,089,000 130,708,000 148,500,000 170,847,000 105,219,000 
        marketable securities
      		58,187,000 99,200,000 171,291,000 186,609,000 228,913,000 248,444,000 298,570,000 267,611,000 205,531,000 264,316,000 246,279,000 125,122,000 136,614,000 143,705,000 150,906,000 127,845,000 132,716,000 141,815,000 152,546,000 63,466,000 13,638,000 26,573,000 93,422,000 114,302,000 234,812,000 266,740,000 315,764,000 315,495,000 310,374,000 123,439,000 
        receivable from contracts with collaborators
      		9,252,000 12,227,000 9,243,000 7,579,000 6,583,000 5,338,000 6,588,000 3,629,000                       
        prepaid expenses and other current assets
      		16,069,000 18,485,000 14,522,000 15,401,000 10,958,000 10,032,000 10,646,000 12,786,000 10,875,000 10,094,000 12,602,000 11,250,000 8,557,000 6,202,000 7,649,000 10,521,000 9,087,000 6,498,000 7,908,000 10,502,000 11,985,000 9,129,000 10,828,000 8,036,000 9,273,000 7,488,000 5,902,000 25,591,000 16,567,000 3,095,000 
        total current assets
      		124,536,000 167,644,000 203,989,000 235,898,000 275,475,000 309,888,000 344,268,000 370,903,000 255,269,000 306,519,000 341,490,000 173,376,000 210,413,000 261,880,000 312,032,000 232,682,000 280,774,000 331,780,000 373,992,000 416,987,000 465,847,000 522,322,000 566,206,000 608,400,000 355,438,000 409,317,000 452,374,000 489,586,000 497,788,000 231,953,000 
        property and equipment
      		59,000 64,000 70,000 76,000 29,000 10,000 302,000 824,000 1,074,000 1,648,000 1,941,000 3,054,000 3,516,000 3,981,000 4,305,000 4,686,000 5,025,000 5,320,000 5,621,000 5,632,000 5,920,000 5,534,000 5,717,000 5,757,000 5,669,000 5,425,000 5,133,000 4,814,000 4,110,000 3,193,000 
        operating lease right-of-use assets
      		3,906,000 4,133,000 4,354,000 4,568,000 4,775,000 5,111,000 6,026,000 1,662,000 2,404,000 3,131,000 3,845,000 4,546,000 5,234,000 5,909,000 6,572,000 7,222,000 7,861,000 5,477,000 6,311,000 8,821,000 9,692,000 10,550,000 11,394,000 10,292,000 9,737,000 10,303,000 10,860,000 11,407,000 11,922,000  
        other assets
      		398,000 408,000 407,000 383,000 310,000 283,000 283,000 59,000 613,000 618,000 649,000 770,000 743,000 680,000 629,000 1,254,000 1,019,000 1,080,000 1,114,000 1,070,000 1,010,000 1,027,000 861,000 627,000 634,000 1,559,000 1,387,000 1,367,000 2,129,000 4,273,000 
        total assets
      		128,899,000 172,249,000 208,820,000 240,925,000 280,589,000 315,292,000 350,879,000 373,448,000 259,360,000 311,916,000 347,925,000 181,746,000 219,906,000 272,450,000 323,538,000 245,844,000 294,679,000 343,657,000 387,038,000 432,510,000 482,469,000 539,433,000 584,178,000 625,076,000 371,478,000 426,604,000 469,754,000 507,174,000 515,949,000 239,419,000 
        liabilities and stockholders' equity
      		                              
        current liabilities
      		                              
        accounts payable
      		10,822,000 5,959,000 1,116,000 1,876,000 3,389,000 2,319,000 3,057,000 1,000,000 2,660,000 5,526,000 1,251,000 2,205,000 2,731,000 1,459,000 363,000 3,908,000 592,000 3,244,000 1,185,000 895,000 1,073,000 7,508,000 865,000 222,000 2,602,000 956,000 2,555,000 3,030,000 4,548,000 2,182,000 
        accrued research and development expenses
      		17,395,000 21,662,000 17,736,000 15,601,000 14,756,000 10,455,000 10,278,000 10,861,000 8,929,000 7,779,000 11,990,000 12,062,000 11,523,000 15,626,000 20,746,000 14,270,000 16,958,000 16,205,000 13,806,000 13,206,000 11,509,000 10,431,000 12,239,000 13,155,000 16,797,000 19,258,000 19,171,000 15,277,000 12,725,000 10,653,000 
        current contract liabilities
      		8,741,000 19,987,000 23,974,000 23,472,000 17,854,000 17,050,000 20,327,000 17,013,000                       
        accrued expenses and other current liabilities
      		19,548,000 15,827,000 19,291,000 12,645,000 12,224,000 15,186,000 17,423,000 16,311,000 14,641,000 26,680,000 17,462,000 14,260,000 14,704,000 20,532,000 31,536,000 26,230,000 17,018,000 20,410,000 20,905,000 15,881,000 16,862,000 20,711,000 19,503,000 14,167,000 8,963,000 16,709,000     
        total current liabilities
      		56,506,000 63,435,000 62,117,000 53,594,000 48,223,000 45,010,000 51,085,000 45,185,000 35,819,000 51,598,000 42,316,000 40,140,000 40,571,000 49,230,000 52,645,000 44,408,000 34,568,000 39,859,000 35,896,000 29,982,000 29,444,000 38,650,000 32,607,000 27,544,000 28,362,000 36,923,000 33,169,000 27,511,000 25,152,000 20,403,000 
        long-term convertible senior notes
      		198,763,000 198,508,000 198,257,000 198,009,000 197,764,000 197,523,000 197,285,000 197,051,000 196,819,000 196,591,000 196,366,000 196,144,000 195,925,000 195,709,000 195,496,000 195,286,000 195,079,000 150,038,000 148,378,000 146,765,000 145,168,000 143,642,000 142,158,000 140,715,000       
        operating lease liabilities - long-term
      		3,213,000 3,460,000 3,700,000 3,934,000 4,170,000 4,398,000 4,593,000   144,000 992,000 1,826,000 2,645,000 3,446,000 4,212,000 4,966,000 5,706,000 3,218,000 3,964,000 6,165,000 6,950,000 7,713,000 8,647,000 7,856,000 8,105,000 8,737,000     
        long-term contract liabilities
      		31,900,000 29,606,000 27,079,000 31,495,000 36,682,000 38,869,000 43,780,000 49,683,000                       
        total liabilities
      		290,382,000 295,009,000 291,153,000 287,032,000 286,839,000 285,800,000 296,743,000 291,919,000 232,638,000 249,147,000 243,308,000 244,546,000 248,362,000 260,373,000 267,187,000 262,305,000 264,520,000 222,194,000 217,229,000 211,817,000 210,385,000 218,749,000 212,077,000 204,752,000 65,015,000 74,119,000 70,881,000 65,730,000 35,689,000 21,121,000 
        commitments and contingencies
      		                              
        stockholders' equity
      		                              
        common stock, 0.0001 par value...
      		24,000 24,000 24,000 23,000 23,000 23,000 23,000 23,000 23,000 23,000 23,000 10,000 10,000 10,000 10,000 8,000 8,000 8,000 8,000 8,000 8,000 8,000 8,000 8,000 7,000 7,000 7,000 7,000 7,000 2,000 
        additional paid-in capital
      		1,328,119,000 1,321,303,000 1,314,450,000 1,302,437,000 1,299,757,000 1,296,848,000 1,291,883,000 1,286,760,000 1,281,295,000 1,275,136,000 1,269,104,000 1,061,555,000 1,053,358,000 1,044,864,000 1,033,385,000 901,141,000 891,121,000 932,944,000 924,914,000 915,414,000 907,089,000 897,607,000 884,677,000 874,863,000 695,205,000 686,390,000 678,010,000 671,913,000 666,648,000 33,853,000 
        accumulated deficit
      		-1,485,602,000 -1,438,938,000 -1,391,700,000 -1,343,479,000 -1,305,206,000 -1,268,568,000 -1,235,539,000 -1,204,736,000 -1,253,968,000 -1,212,040,000 -1,163,892,000 -1,123,884,000 -1,081,388,000 -1,032,223,000 -976,459,000 -917,096,000 -860,630,000 -811,534,000 -755,250,000 -695,003,000 -635,171,000 -577,530,000 -512,926,000 -455,114,000 -388,244,000 -334,170,000 -279,472,000 -230,972,000 -186,474,000 -153,863,000 
        accumulated other comprehensive loss
      		-4,024,000      -2,231,000 -518,000 -628,000 -350,000 -618,000 -481,000 -436,000                 -61,000 
        total stockholders' deficit
      		-161,483,000                             -120,069,000 
        total liabilities and stockholders' equity
      		128,899,000 172,249,000 208,820,000 240,925,000 280,589,000 315,292,000 350,879,000 373,448,000 259,360,000 311,916,000 347,925,000 181,746,000 219,906,000 272,450,000 323,538,000 245,844,000 294,679,000 343,657,000 387,038,000 432,510,000 482,469,000 539,433,000 584,178,000 625,076,000 371,478,000      
        accumulated other comprehensive income
      		 -5,149,000 -5,107,000 -5,088,000 -824,000 1,189,000         -585,000 -514,000 -340,000 45,000 137,000 274,000 158,000 599,000 342,000 567,000 -505,000 258,000 328,000 496,000 79,000  
        total stockholders' equity
      		 -122,760,000 -82,333,000 -46,107,000 -6,250,000 29,492,000 54,136,000 81,529,000 26,722,000 62,769,000 104,617,000 -62,800,000 -28,456,000 12,077,000 56,351,000 -16,461,000 30,159,000 121,463,000 169,809,000 220,693,000 272,084,000 320,684,000 372,101,000 420,324,000 306,463,000 352,485,000 398,873,000 441,444,000 480,260,000  
        current portion of long-term debt
      		        9,589,000 11,613,000 11,613,000 11,613,000 11,613,000 11,613,000                 
        long-term debt
      		         814,000 3,634,000 6,436,000 9,221,000 11,988,000 14,834,000 17,645,000 29,167,000 29,079,000 28,991,000 28,905,000 28,823,000 28,744,000 28,665,000 28,637,000 28,548,000 28,459,000 28,370,000 28,281,000   
        restricted cash
      		                64,000 64,000 64,000 566,000 565,000 565,000        200,000 
        accumulated other comprehensive (deficit) income
      		             -574,000                 
        liabilities, convertible preferred stock, and stockholders' equity
      		                              
        preferred stock, 0.0001 par value...
      		                              
        accrued expenses - long-term
      		                             718,000 
        series seed convertible preferred stock, 0.0001 par value...
      		                             29,200,000 
        series a convertible preferred stock, 0.0001 par value...
      		                             79,615,000 
        series b convertible preferred stock, 0.0001 par value...
      		                             229,552,000 
        total liabilities, convertible preferred stock and stockholders' equity
      		                         426,604,000 469,754,000 507,174,000 515,949,000  
        accrued expenses
      		                          11,443,000 9,204,000 7,879,000 7,568,000 
        operating lease liabilities
      		                          9,342,000 9,938,000 10,537,000  
        commitments and contingencies - note 10
      		                              
        liabilities, convertible preferred stock, and stockholders' deficit
      		                              
        accrued interest
      		                              
        note payable to related parties
      		                              
        convertible note payable
      		                              
        stockholders' deficit
      		                              
        total liabilities, convertible preferred stock and stockholders' deficit
      		                             239,419,000 
      Cashflow Statements:
      Quarterly
      Annual
        Unit: USD2026-03-31 2025-12-31 2025-09-30 2025-06-30 2025-03-31 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2022-06-30 2022-03-31 2021-12-31 2021-09-30 2021-06-30 2021-03-31 2020-12-31 2020-09-30 2020-06-30 2020-03-31 2019-12-31 2019-09-30 2019-06-30 2019-03-31 
                                     
          cash flows from operating activities
        		                             
          net loss
        		-46,664,000 -47,238,000   -36,638,000 -33,029,000   -41,928,000 -48,148,000 -40,008,000 -42,496,000 -49,165,000 -55,764,000 -59,363,000 -56,466,000 -57,785,000 -56,284,000 -60,247,000 -59,832,000 -57,641,000 -64,604,000 -57,812,000 -66,870,000 -54,074,000 -54,698,000 -48,500,000 -44,498,000 -32,611,000 
          adjustments to reconcile net loss to net cash from operating activities:
        		                             
          depreciation and amortization expense
        		5,000  6,000 6,000 6,000  216,000 250,000 259,000  387,000 463,000 465,000  460,000 460,000 452,000             
          stock-based compensation expense
        		6,304,000 2,898,000 2,666,000 2,586,000 2,405,000 4,965,000 4,842,000 5,001,000 5,811,000 6,032,000 6,162,000 8,197,000 8,127,000 11,449,000 10,122,000 9,999,000 10,983,000 7,659,000 7,587,000 8,054,000 8,708,000 12,681,000 8,923,000 8,900,000 8,244,000 6,862,000 5,728,000 5,140,000 3,089,000 
          amortization of operating lease right-of-use assets
        		227,000 221,000 214,000 207,000 336,000 967,000 882,000 742,000 727,000 714,000 701,000 688,000 675,000 663,000 650,000 639,000 645,000 834,000 864,000 871,000 858,000 844,000 812,000 637,000 566,000     
          amortization of long-term debt discount and issuance costs
        		255,000 251,000 248,000 245,000 241,000 238,000 234,000 321,000 293,000 308,000 323,000 338,000 352,000 270,000 302,000 299,000 292,000        89,000 89,000 89,000   
          amortization of premium on marketable securities, net of accretion of discounts
        		-660,000  -1,585,000 -1,944,000 -2,667,000  -3,658,000 -2,993,000 -3,047,000       20,000 125,000             
          changes in operating assets and liabilities:
        		                             
          receivable from contracts with collaborators
        		2,975,000 -2,984,000 -1,664,000 -996,000 -1,245,000 1,250,000 -2,959,000                       
          prepaid expenses and other current assets
        		2,416,000 -3,963,000 879,000 -4,443,000 -926,000 614,000 2,140,000 -1,911,000 -781,000 2,508,000 -1,352,000 -2,693,000 -2,355,000 1,447,000 2,872,000 -1,434,000 -2,589,000 1,410,000 2,594,000 1,482,000 -2,855,000 1,699,000 -2,792,000 1,237,000 -1,785,000 -1,586,000 1,436,000 -771,000 -3,472,000 
          other assets
        		10,000 -1,000 -24,000 -73,000 -27,000 0 -224,000 554,000 5,000 31,000 121,000 -27,000 -63,000 -51,000 625,000 -235,000 61,000 34,000 -44,000 -59,000 16,000 -166,000 -234,000 7,000 925,000 -172,000 -20,000 762,000 2,144,000 
          operating lease liabilities
        		-227,000 -222,000 -205,000 -198,000 -336,000 -1,035,000 -731,000 -819,000 -801,000 -766,000 -753,000 -740,000 -723,000 -691,000 -680,000 -667,000 -683,000 -874,000 -928,000 -1,895,000 117,000 -1,557,000 -579,000 -149,000 -566,000     
          accounts payable
        		6,156,000 4,822,000 -795,000 -5,837,000 -937,000 3,080,000 -295,000 -1,517,000 -2,924,000 4,262,000 -988,000 -507,000 1,223,000 285,000 -3,302,000 3,711,000 -2,507,000 2,380,000 -177,000 -66,000 -6,565,000 6,974,000 737,000 -2,336,000 1,609,000 -1,732,000 -490,000 -1,309,000 2,132,000 
          accrued expenses and other current liabilities
        		-234,000  1,308,000 -127,000 490,000  -3,496,000 2,991,000 -9,273,000  -204,000 -778,000 -273,000                 
          accrued research and development expenses
        		-4,267,000 3,926,000 2,135,000 845,000 4,301,000 177,000 -583,000 1,932,000 1,150,000 -4,211,000 -72,000 539,000 -4,103,000 -5,120,000 6,476,000 -2,688,000 753,000 2,399,000 600,000 1,697,000 1,078,000 -1,808,000 -916,000 -3,642,000 -2,461,000 87,000 3,894,000 2,552,000 2,072,000 
          accrued compensation and benefits
        		1,435,000 -759,000 2,809,000 3,010,000 -5,844,000 1,991,000 2,186,000 2,102,000 -4,578,000 1,243,000 852,000 2,782,000 -8,117,000 3,033,000 1,771,000 2,616,000 -5,802,000 3,640,000 340,000 2,242,000 -6,500,000 3,571,000 1,016,000 2,658,000 -5,633,000 2,917,000 2,075,000 1,757,000 -1,569,000 
          contract liabilities
        		-8,952,000 -1,460,000 -3,914,000 431,000 -1,383,000 -8,188,000 -2,589,000                       
          accrued interest expense
        		2,500,000    2,500,000 -2,500,000 2,500,000 -2,604,000 2,469,000 -2,527,000 2,473,000 -2,527,000 2,484,000 -2,484,000 2,491,000 -2,508,000 2,500,000             
          net cash from operating activities
        		-38,721,000 -48,314,000   -39,724,000 -35,481,000 -32,033,000 116,348,000 -52,302,000 -33,424,000 -34,494,000 -38,251,000 -52,989,000 -47,730,000 -36,997,000 -48,822,000 -53,483,000 -40,509,000 -42,035,000 -47,450,000 -58,896,000 -36,736,000 -44,930,000 -42,399,000 -52,295,000 -44,140,000 -36,110,000 -36,810,000 -27,774,000 
          capital expenditures
        		 0   -26,000 0 0 0 0 0 0 0  -68,000 -31,000 -120,000 -157,000 -83,000 -523,000 -138,000 -802,000 -250,000 -299,000 -441,000 -513,000 -528,000 -711,000 -1,380,000 -347,000 
          free cash flows
        		 -48,314,000   -39,750,000 -35,481,000 -32,033,000 116,348,000 -52,302,000 -33,424,000 -34,494,000 -38,251,000  -47,798,000 -37,028,000 -48,942,000 -53,640,000 -40,592,000 -42,558,000 -47,588,000 -59,698,000 -36,986,000 -45,229,000 -42,840,000 -52,808,000 -44,668,000 -36,821,000 -38,190,000 -28,121,000 
          cash flows from investing activities
        		                             
          purchase of marketable securities
        		-24,994,000 -20,988,000 -29,586,000 -75,521,000 -101,012,000 -83,684,000 -131,354,000 -193,612,000 -86,127,000 -120,266,000 -188,092,000 -56,449,000 -76,863,000 -77,419,000 -88,052,000 -35,186,000 -37,403,000 -8,134,000 -93,974,000   1,000 -35,192,000 1,000 -73,778,000     
          maturities of marketable securities
        		66,600,000 87,000,000 46,600,000 119,700,000 123,100,000 136,900,000 104,600,000 134,500,000 147,800,000 105,900,000 69,800,000 69,400,000 85,600,000 86,000,000 65,500,000 40,000,000 46,000,000 18,675,000 4,750,000 0 12,800,000 66,649,000 55,725,000 54,221,000 89,083,000     
          purchase of property and equipment
        		 0 0 -53,000 -26,000         -102,000 -31,000 -120,000 -157,000 -83,000 -523,000 -138,000 -802,000 -250,000 -299,000 -441,000 -513,000 -528,000 -711,000 -1,380,000 -347,000 
          net cash from investing activities
        		41,606,000 73,156,000 17,014,000 44,126,000 22,062,000 53,216,000 -26,754,000 -59,112,000 61,673,000 -14,366,000 -118,262,000 12,936,000 8,722,000 8,464,000 -22,598,000 4,679,000 8,420,000 10,443,000 -89,762,000 -50,076,000 11,968,000 61,100,000 19,959,000 106,245,000 28,038,000 46,933,000 17,949,000 -13,884,000 -198,142,000 
          cash flows from financing activities
        		                             
          proceeds from issuance of common stock pursuant to employee stock purchase plan
        		292,000  469,000 0 372,000  281,000 0 348,000  77,000 0 367,000  620,000               
          proceeds from the exercise of stock options
        		220,000 1,239,000 465,000 94,000 132,000         13,000 1,576,000 21,000 126,000 371,000 1,357,000 271,000 15,000 249,000 131,000 139,000 15,000 1,518,000 369,000 87,000 71,000 
          net cash from financing activities
        		512,000 3,955,000 1,872,000 94,000 504,000 0 281,000 -9,214,000 -2,555,000 -2,903,000 198,497,000 -2,904,000 -2,536,000 -2,873,000 119,221,000 21,000 721,000 371,000 1,913,000 271,000 774,000 249,000 891,000 310,829,000 571,000 1,518,000 369,000 28,347,000 291,344,000 
          effect of exchange rate changes on cash and cash equivalents
        		-101,000 2,000 -95,000 129,000 105,000 -125,000 93,000 -8,000 -62,000  -136,000 -19,000 72,000          -26,000 34,000 -50,000     
          net increase in cash and cash equivalents
        		3,296,000   -2,712,000 -17,053,000   48,014,000 6,754,000              -24,080,000 374,675,000 -23,686,000     
          cash and cash equivalents, at the beginning of the period
        		37,732,000 0 0 0 46,074,000 0 0 0 32,109,000    111,973,000          0 0 135,089,000     
          cash and cash equivalents, at the end of the period
        		41,028,000 28,799,000 -17,376,000 -2,712,000 29,021,000 17,610,000                 -24,106,000 374,709,000 111,353,000     
          supplemental disclosure of cash flow information:
        		                             
          cash paid for interest
        		 5,000,000 0   5,000,000 0 5,194,000 367,000 5,457,000 548,000 5,620,000 663,000 5,670,000 677,000 5,690,000 675,000 5,683,000 690,000 5,690,000 675,000 5,960,000 668,000 625,000 618,000 621,000    
          supplemental disclosure of noncash investing and financing activities:
        		                             
          change in unrealized gain on marketable securities
        		-67,000 -22,000 111,000 -69,000 -110,000 -274,000 547,000 -25,000 -159,000  33,000 -46,000 115,000                 
          depreciation and amortization
        		                 448,000 450,000 426,000 416,000 365,000 365,000 350,000 329,000 292,000 251,000 205,000 169,000 
          in process research and development expenses
        		 -1,000          15,000 15,000 15,000 15,000 15,000 20,000 15,000 15,000 15,000 30,000 5,300,000 275,000 15,000,000 2,805,000 1,600,000 0 1,000,000 1,000,000 
          amortization of premium on investments, net of accretion of discounts
        		                 153,000 71,000 49,000 66,000 74,000 57,000 32,000 -65,000 -68,000 -832,000   
          net realized gain on investments
        		                     0 -3,000 -214,000 -39,000 -27,000 0   
          loss on disposal of property and equipment
        		     185,000 305,000 0 316,000 0        -64,000            
          accrued expenses
        		             -98,000 970,000 -2,583,000 52,000 -3,979,000 5,057,000 -2,113,000 1,771,000 -1,672,000 3,750,000 1,257,000 -2,239,000 2,281,000 258,000 -229,000 -789,000 
          sales of marketable securities
        		                     0 0 67,464,000 16,051,000     
          proceeds from issuance of common stock and warrants in a private offering, net of offering costs
        		                             
          proceeds from issuance of common stock under employee stock purchase plan
        		                             
          proceeds from the exercise of warrants
        		 2,717,000                            
          proceeds from issuance of equity option pursuant to stock purchase agreement
        		                             
          principal repayments of long-term debt
        		     0 0 -9,678,000 -2,903,000 -2,903,000 -2,903,000 -2,904,000 -2,903,000 -2,903,000                
          right-of-use assets obtained in exchange for lease liabilities
        		                     0 1,914,000       
          proceeds from grant of equity option pursuant to chiesi collaboration agreement
        		      0                       
          net decrease in cash and cash equivalents
        		          45,605,000 -28,238,000 -46,731,000                 
          operating lease right-of-use asset obtained in exchange for lease liability
        		              0 0 3,029,000             
          net income
        		                             
          adjustments to reconcile net income to net cash from operating activities:
        		                             
          net cash provided (used) in operating activities
        		                             
          research and development asset acquisitions, net of cash acquired
        		           -15,000 -15,000 -15,000 -15,000 -15,000 -20,000 -15,000 -15,000 -15,000 -30,000 -5,300,000 -275,000 -15,000,000 -2,805,000 -1,600,000 0 -1,000,000 -1,000,000 
          purchases of property and equipment included in accounts payable and accrued expenses and other current liabilities
        		             34,000                
          proceeds from issuance of common stock and common warrants in a private offering, net of offering costs
        		                             
          cash, cash equivalents and restricted cash, at the end of the period
        		       48,014,000 38,863,000 -50,500,000 45,605,000 -28,238,000 65,242,000 -41,504,000 59,161,000 -44,655,000 138,971,000 -30,071,000 -129,481,000 -97,205,000 440,224,000     4,381,000 -17,792,000 -22,347,000 170,847,000 
          amortization of discount (premium) on investments, net of accretion of discounts
        		                             
          effect of exchange rate changes on cash, cash equivalents and restricted cash
        		             635,000 -465,000 -533,000 -154,000 -376,000 403,000 50,000 -242,000         
          net decrease in cash, cash equivalents and restricted cash
        		              59,161,000 -44,655,000 -44,496,000    -46,154,000         
          cash, cash equivalents and restricted cash, at the beginning of the period
        		         0 0   0 0 0 183,467,000 0 0 0 486,620,000     0 0 0 105,419,000 
          derecognition rou lease assets obtained in exchange for operating lease liabilities
        		                 0            
          change in unrealized loss on marketable securities
        		                             
          amortization of discount on marketable securities, net of accretion of discounts
        		                             
          amortization of premium (discount) on marketable securities, net of accretion of discounts
        		           -1,505,000 -1,531,000                 
          net realized loss on investments
        		                             
          proceeds from issuance of common stock in a public offering
        		                     0 16,000   0 0 38,000 291,273,000 
          proceeds from issuance of convertible senior notes
        		                             
          proceeds from issuance of common stock in a private offering, net of offering costs
        		             18,000                
          purchase of shares pursuant to employee stock purchase plan
        		                595,000 0 556,000 0 759,000 0 744,000 0 556,000     
          net increase in cash, cash equivalents and restricted cash
        		                 -30,071,000 -129,481,000       4,311,000 -17,792,000 -22,347,000 65,428,000 
          change in unrealized loss on marketable securities, net of tax
        		                -377,000             
          proceeds from the issuance of long-term debt, net of debt discount and issuance costs 1,778
        		                             
          conversion of convertible preferred stock to common stock
        		                         0 0 0 338,367,000 
          change in unrealized gain on marketable securities, net of tax
        		                 -413,000 303,000 -46,000 -69,000 -125,000 -293,000 994,000 -676,000 -179,000 -55,000 425,000 140,000 
          amortization of debt discount and issuance costs
        		                  1,699,000 1,679,000 1,605,000  1,471,000       
          proceeds from issuance of convertible debt
        		                      0       
          unpaid property and equipment
        		                     -68,000 26,000 -3,000 60,000 56,000 -141,000 -471,000 739,000 
          proceeds from issuance of series a convertible preferred stock
        		                             
          proceeds from issuance of series b convertible preferred stock
        		                             
          repayment of notes payable to related parties
        		                             
          payment of deferred offering costs
        		                             
          acquisition of in-process research and development through issuance of stock
        		                             
          issuance of series a convertible preferred stock to convert debt and accrued interest
        		                             
          unpaid deferred offering costs - net
        		                             
          proceeds from the issuance of long-term debt, net of issuance costs of 1,778
        		                          0   
          proceeds from issuance of convertible note
        		                             
          proceeds from the issuance of long-term debt, net of debt discount and issuance costs of 1,778
        		                             
          operating lease right of use assets and liabilities
        		                          1,000 -13,000 61,000 
          purchase of investments
        		                          -112,355,000 -64,743,000 -222,295,000 
          maturities of investments
        		                          130,853,000   
          sales of investments
        		                          162,000   
          recognition of operating lease right of use asset
        		                          0 0 12,458,000 
          recognition of operating lease liabilities
        		                          0 0 13,182,000 
          change in unrealized loss on foreign currency translations, net of tax
        		                          113,000   
          sales and maturities of investments
        		                            25,500,000 
          accrued interest - short-term
        		                             
          proceeds from long term note payable
        		                             
          acquisition of in process research and development through issuance of stock